◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › PVLA

Palvella Therapeutics, Inc. (PVLA) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-21

Palvella Therapeutics, Inc. (PVLA) operates in the Biotechnology industry and is headquartered in Wayne, United States with about 29 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, PVLA reported $0M in revenue and ($42M) in net income.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Interactive charts & full statements →

PVLA Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($39M)($14M)($12M)($18M)
Net Income($42M)($17M)$19M($28M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PVLA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($15M)($11M)($10M)($9M)($8M)
Net Income($16M)($13M)($11M)($10M)($8M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PVLA Free Cash Flow History

PVLA Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-31
Total Assets$60M$88M$8M$16M
Total Liabilities$32M$26M$11M$40M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PVLA viewer.

Other Companies in Biotechnology

← PVHAll stocksPWP →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.